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The value of combination chemotherapy in advanced oesophago-
gastric cancer has been clarified. Three randomized clinical trials
have demonstrated the superiority of chemotherapy over best
supportive care alone (Murad et al, 1993; Pyrhonen et al, 1995;
Glimelius et al, 1997). However, the optimal regimen has not yet
been established. The combination of 5-fluorouracil (5-FU),
adriamycin and methotrexate (FAMTX) has been considered
standard therapy, with superior response and survival rates
compared with previous regimens (Wils et al, 1991; Kelsen et al,
1992). A combination of cisplatin, epirubicin, leucovorin and 5-FU
(PELF) has also demonstrated impressive response rates in a
randomized study (Cocconi et al, 1994). The regimen of epirubicin,
cisplatin and 5-FU (ECF) was developed at the Royal Marsden
Hospital (RMH) and first reported in 1991 (Cunningham et al,
1991). The three drugs in this regimen were selected on the basis of
their single agent activity in upper gastrointestinal tract tumours
(Beer et al, 1983; Cersosimo and Hong, 1986; Machover et al,
1986), and on the synergy demonstrated between 5-FU and cisplatin
in preclinical models (Etienne et al, 1991). The 5-FU is delivered as
a protracted infusion as this schedule has produced higher response
rates with less myelotoxicity compared with bolus administration in
patients with colorectal cancer (Lokich et al, 1989). Following the
demonstration of response rates of 71% with moderate toxicity in a
phase II study (Findlay et al, 1994), we undertook a multicentre
randomized study comparing ECF with FAMTX in advanced
oesophagogastric cancer. The initial results of this trial were
reported in 1996 when recruitment was completed (Webb et al,
1997). At that stage, an advantage for ECF in response rate and
survival was evident. However, median follow-up was only 6.1
months and only 75% of patients had died. We now present a final
survival analysis with all patients followed up for 26.9 months or
more (median 44 months), and 95% of patients having died.
METHODS
Our methods have been described previously (Webb et al, 1997).
Briefly, patients with inoperable adenocarcinoma or undifferenti-
ated carcinoma of the oesophagus, oesophagogastric junction,
or stomach were randomized to receive ECF or FAMTX
chemotherapy. ECF chemotherapy was administered through a
central venous catheter placed in the subclavian vein. 5-FU was
given as a continuous intravenous infusion at a dose of 200 mg m–2
day–1 for up to 6 months. Epirubicin (50 mg m–2) and cisplatin
(60 mg m–2) were given every 3 weeks to a maximum of 8 cycles.
FAMTX chemotherapy comprised methotrexate 1500 mg m–2 and
5-FU 1500 mg m–2 on day 1, and doxorubicin 30 mg m–2 on day
15. Cycles were repeated every 28 days to a maximum of 24
weeks. Patients were followed up with clinical and symptomatic
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Keywords: cancer; chemotherapy; ECF; FAMTX; gastric; oesophagogastric
269
British Journal of Cancer (1999) 80(1/2), 269–272
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0350
Received 27 August 1998
Revised 4 November 1998
Accepted 6 November 1998
Correspondence to: D Cunninghamassessment at each visit, and computerized tomography (CT) scan
and endoscopy at 12 and 24 weeks from the start of treatment.
Responses were classified according to World Health Organization
(WHO) criteria (Miller et al, 1981). In addition, histological
confirmation at endoscopy or surgery was required to satisfy the
definition of complete remission. Statistical methods used in the
design and analysis of this trial have been described previously
(Webb et al, 1997). Tumour response rates in the two arms were
compared using the c2 test. Patient survival and failure-free
survival was examined using the Kaplan–Meier product-limit
method, and treatment arms were compared with the log-rank test.
Participants gave written informed consent before they entered the
study, which was approved by the individual institutes’ Ethics
Committee.
RESULTS
Between July 1992 and June 1995, 274 patients (137 in each arm)
were randomized from eight oncology centres in the UK. Eighteen
patients were ineligible as described in our previous report (Webb
et al, 1997), and were excluded from the analysis. Therefore, 256
patients (126 ECF and 130 FAMTX) were assessable on an inten-
tion-to-treat basis. The patient characteristics were well matched
between treatment groups (Webb et al, 1997).
Response
Response analysis is now complete and includes 237 evaluable
patients (121 ECF and 116 FAMTX). A detailed analysis is
presented in Table 1. The response rate was 46% (95% confidence
interval (CI), 37–55%) in the ECF arm, and 21% (95% CI,
13–28%) in the FAMTX arm (P = 0.00003). The response rate for
locally advanced disease was 58% (95% CI, 43–72%) (eight
complete responses and 17 partial responses) for ECF and 20%
(95% CI, 9–34%) (two complete responses and seven partial
responses) for FAMTX (P = 0.0002). For metastatic disease, the
response rate was 40% (95% CI, 29–52%) for ECF and 21% (95%
CI, 13–33%) for FAMTX.
Survival
All eligible patients were included in the survival analysis on an
intention-to-treat basis. All surviving patients have now been
followed up for at least 26.9 months (median 44 months), and 95%
of patients have died. The median survival time was 8.7 months
with ECF and 6.1 months with FAMTX (P = 0.0005) (Figure 1).
The 1- and 2-year survival rates were 37% (95% CI, 28–45%) and
14% (95% CI, 8–20%) for the ECF arm, and 22% (95% CI,
15–29%) and 5% (95% CI, 2–10%) for the FAMTX arm. The
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Table 1 Overall objective response rates
ECF FAMTX
(n = 121) (n = 116)
Response No. % No. % P
CR + PR 56 46 24 21 0.00003
CR 10 8 2 2
PR 46 38 22 19
SD 25 21 24 21
PD 23 19 43 37
Insufficient treatment
Early death 7 17
Toxic death 1 2
Toxicity 5 6
Patient request 4 –
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease.
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Figure 1 Overall survival curvemedian failure-free survival time was 7.4 months with ECF and
3.3 months with FAMTX (P < 0.0001) (Figure 2).
Surgery
Twenty-five patients have had a surgical procedure following
chemotherapy (19 ECF and six FAMTX). Resection was not
possible or the procedure was performed purely for palliation of
symptoms in seven patients (six ECF and one FAMTX). Five
patients had attempted resection of their tumour, but histological
examination revealed that excision was incomplete (four ECF and
one FAMTX). A histologically complete resection was performed
in ten patients in the ECF arm, three of whom had a pathological
complete response to chemotherapy. Four patients treated with
FAMTX had a complete resection with no pathological complete
responses.
Long-term survival
Twenty-four patients have survived for 2 or more years (range
24.6–55.1 months) from randomization (17 (13.5%) ECF and
seven (5.4%) FAMTX; P = 0.03). Thirteen patients in the ECF arm
and three in the FAMTX arm had locally advanced disease.
Potentially curative surgery was performed in nine of these
patients following chemotherapy (seven ECF and two FAMTX),
and consolidation radiotherapy performed in two (both ECF). A
total of eight patients (five ECF and three FAMTX) have gone on
to receive treatment with a variety of palliative chemotherapy regi-
mens following progressive or recurrent disease, and six patients
have received no further active treatment. Thirteen patients remain
alive (26.9–55.1 months from randomization), of whom eight are
free of disease: six patients in the ECF arm and one in the FAMTX
arm who subsequently had a complete surgical resection, and one
patient treated with ECF who had initially been referred for
chemotherapy following an incomplete surgical resection and
received no additional treatment subsequently.
DISCUSSION
We have shown a definite advantage for the ECF regimen over
FAMTX in the treatment of advanced oesophagogastric adenocarci-
noma. This final analysis confirms and strengthens the conclusions
of our initial analysis of this study (Webb et al, 1997), showing
improved response rates and survival for the ECF arm, which are
sustained beyond 2 years. High levels of activity have been demon-
strated for a number of regimens in phase II studies (Preusser et al,
1989; Murad et al, 1993; Findlay et al, 1994), but randomized
comparisons with established regimens have often shown little or no
advantage for the new regimen (Kelsen et al, 1992; Wilke et al,
1995). The EORTC study comparing FAMTX with 5-FU, doxo-
rubicin and mitomycin (FAM) (Wils et al, 1991) was the first study
demonstrating a survival advantage between chemotherapy regi-
mens, and FAMTX has remained the gold standard of therapy.
Another recently reported phase II study has investigated a
weekly regimen incorporating cisplatin, leucovorin-modulated
5-FU and epirubicin, with granulocyte colony-stimulating factor
and glutathione support (Cascinu et al, 1997). A response rate of
62% was reported, with a median survival of 11 months. The
response rate of the ECF regimen was 71% in the phase II study
(Findlay et al, 1994). The lowering of the response rate in this phase
III randomized trial is likely to be due to elimination of case-selec-
tion bias, a commonly observed phenomenon. ECF would therefore
be an appropriate regimen to act as comparator in future trials.
Long-term survival in advanced oesophagogastric cancer is very
rare. Previous studies have reported 2-year survival rates for the
FAMTX regimen of 9–10% (Wils et al, 1991; Murad et al, 1993).
In our study, ECF produced a 2-year survival rate of 13.5%
compared with 5.4% for FAMTX. It is notable that ECF
chemotherapy resulted in tumour downstaging sufficient to allow
complete resection of previously inoperable tumours in ten
patients, three of whom had no residual tumour in the resected
specimen. Six of these patients remain disease-free. In contrast,
only four patients treated with FAMTX had complete resections
performed, only one of whom is currently disease-free.
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Figure 2 Failure-free survival curveThe results of surgery alone in oesophagogastric cancer are poor.
Five-year survival rates of 21% have been reported following cura-
tive resection (Allum et al, 1989). The high response rates seen
with ECF, particularly in patients with locally advanced disease,
and the extended survival of patients going on to have complete
surgical excision of residual disease provide support for the use of
ECF in neoadjuvant therapy. Surgeons should be reassured by the
low rates of progressive disease with this regimen. In this trial, only
5% of patients with locally advanced disease progressed while on
ECF chemotherapy and are likely to represent a poor prognostic
group. Rather than delaying surgery, neoadjuvant ECF may in fact
render tumours more easily resectable, allowing more curative
procedures to be undertaken. A number of phase II studies have
investigated preoperative chemotherapy with a variety of regimens
in oesophagogastric cancer, both in patients with resectable and
non-resectable disease (Wilke et al, 1989; Plukker et al, 1991,
1995; Rougier et al, 1994; Melcher et al, 1996). These support
the principle of neoadjuvant chemotherapy, producing extended
disease-free and overall survival compared with historical controls.
High rates of complete resection have been reported in patients
with initially unresectable locally advanced disease. These series
are difficult to compare because of different criteria for selecting
patients, and the small numbers of patients involved. The MAGIC
trial, which randomizes patients with operable gastric cancer to
receive peri-operative ECF or surgery alone, currently being under-
taken by the Medical Research Council in conjunction with the
British Gastric Cancer Group, will provide definitive evidence as to
the efficacy of this approach.
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